Other
placebo matching canakinumab
placebo matching canakinumab is an intervention with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_2
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
NCT00819585
completedphase_2
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
NCT00663169
Clinical Trials (2)
Showing 2 of 2 trials
NCT00819585Phase 2
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
NCT00663169Phase 2
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
All 2 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 2